Every 424B that CERO TERAPEUTICS HLDG INC (CERO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow CERO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CERO filings page.
CERo Therapeutics Holdings, Inc. has filed Prospectus Supplement No. 15 to its Form S-1, covering 729,596,950 shares of common stock, to incorporate its Quarterly Report for the period ended June 30, 2026. The common stock trades on OTCQB under “CERO” and public warrants on OTCID under “CEROW”. On August 13, 2026, the last quoted bid prices were $0.0095 per share of common stock and $0.0025 per warrant.
As of June 30, 2026, CERo reported cash, restricted cash, and cash equivalents of $937,512, total assets of $1.9 million, and total liabilities of $32.4 million, resulting in a stockholders’ deficit of $30.5 million. The company recorded a six‑month net loss of $6.9 million and an accumulated deficit of $97.8 million, and disclosed substantial doubt about its ability to continue as a going concern without additional capital. There were 63,811,396 common shares outstanding as of June 30, 2026.
CERO Therapeutics Holdings, Inc. has filed a prospectus supplement linked to an existing registration statement covering 729,596,950 shares of common stock, updating it with details of a new convertible financing. The common stock trades on OTCQB under “CERO,” with a last quoted bid of $0.0115 per share on July 16, 2026, and public warrants “CEROW” quoted at $0.0048 per warrant.
On July 14, 2026, the company entered into a second amended and restated convertible grid promissory note with SRX Global Inc. The Note allows tranche funding of up to $2,085,200, corresponding to a principal amount of up to $2,606,500 with a 25% original issue discount. Tranches of $750,000, $663,600, and $671,600 have been funded. The Note bears 10% annual interest, matures on May 28, 2027, and is convertible at the lender’s option at the lesser of $0.05 per share or 80% of the average of the five lowest intraday trading prices over the 20 days before a conversion request, subject to a 4.99% beneficial ownership limitation. The company is obligated to file a registration statement on Form S-1 or S-3 to register the resale of the conversion shares.
CERO Therapeutics Holdings, Inc. files Prospectus Supplement No. 13 to its Form S-1 registering 729,596,950 shares of common stock. The supplement attaches a Form 8-K that discloses an amended and restated convertible promissory note providing up to $1,413,600 in aggregate loans, of which $750,000 was previously funded and an additional $663,600 funded on June 23, 2026. The Note bears interest at 10% per annum, matures on May 28, 2027, and is convertible into common stock at the lesser of $0.05 per share or 80% of a short-term average trading price, subject to a 4.99% beneficial ownership limitation. The supplement also states the company will file a registration statement covering resale of shares issuable upon conversion.
CERO Therapeutics Holdings, Inc. is registering 729,596,950 shares of Common Stock via a Prospectus Supplement. The supplement attaches a Form 8-K that discloses the company issued a convertible promissory note on May 28, 2026.
The Note was purchased for $750,000 (principal face value $937,500), bears interest at 10% per annum, matures on May 28, 2027, and is convertible into Common Stock at a conversion price equal to the lesser of $0.05 or 80% of the average of the five lowest intraday trading prices during the twenty days before conversion, subject to a 4.99% beneficial ownership limitation. The Note requires the company to file a registration statement covering resale of shares issuable on conversion. The prospectus supplement also states recent bid prices: Common Stock $0.0191 and public warrants $0.0022.
CERo Therapeutics Holdings, Inc. files a Prospectus Supplement registering 729,596,950 shares of Common Stock. The supplement incorporates the Company’s Form 10-Q for the quarter ended March 31, 2026 into the S-1 prospectus and updates disclosure, including liquidity and balance sheet items from the attached 10-Q.
The 10-Q shows cash, restricted cash, and cash equivalents of $857,489, a working capital deficit of approximately $9.8 million, a net loss of $5,885,914 for the three months ended March 31, 2026, and derivative liabilities measured at $2,396,722 as of March 31, 2026. The supplement should be read together with the Prospectus and replaces inconsistent prior Prospectus language.
CERO Therapeutics Holdings, Inc. filed Prospectus Supplement No. 10 to its Form S-1 registering 729,596,950 shares of Common Stock and attached a Form 8-K describing a convertible note financing.
The company issued a convertible promissory note with a purchase price of $400,000 (principal face value $500,000), permitting borrowings up to $1,000,000. The Note bears 10% interest, matures on April 27, 2027, and is convertible at the lesser of $0.05 per share or 80% of the average of the five lowest intraday prices during the 20 days prior to conversion, subject to a 4.99% beneficial ownership limitation. The company agreed to file a registration statement covering resale of shares issuable on conversion.
CERo Therapeutics Holdings, Inc. registered 729,596,950 shares of Common Stock via Prospectus Supplement No. 9 to its Form S-1. This Prospectus Supplement amends and supplements the December 5, 2025 prospectus by attaching Amendment No. 1 to the Company’s Form 10-K (filed April 30, 2026).
The supplement states the Company’s common stock trades on OTCQB under the symbol CERO with a last quoted bid of $0.0327 per share and its public warrants trade under CEROW with a last quoted bid of $0.0025. The supplement should be read together with the Prospectus and the attached Form 10-K/A.
CERo Therapeutics Holdings, Inc. registers 729,596,950 shares of Common Stock. This Prospectus Supplement No. 8 amends the Prospectus dated December 5, 2025 and attaches the Company’s Annual Report on Form 10-K filed April 15, 2026.
The supplement notes trading on OTCQB as “CERO” and OTCID warrants as “CEROW,” provides last quoted bid prices of $0.0320 per share (common stock) and $0.0035 per warrant as of April 14, 2026, and states that CERo is an emerging growth company. The Form 10-K discloses 36,786,686 shares outstanding as of April 14, 2026 and summarizes preclinical and Phase 1 clinical progress for lead candidate CER-1236, including FDA orphan and Fast Track designations and that five patients have been dosed in the ongoing Phase 1 AML study.
Cero Therapeutics Holdings, Inc. files Prospectus Supplement No. 7 to its Form S-1 registering 729,596,950 shares of common stock.
The supplement attaches a Form 8-K that discloses a convertible promissory note: a $350,000 purchase (principal face value $437,500) under a facility allowing borrowings up to $1,000,000, bearing interest at 10%, maturing April 9, 2027, and convertible into common stock at the lesser of $0.05 or 80% of the average of the five lowest intraday trading prices during the prior 20 days, subject to a 4.99% beneficial ownership cap. The note requires registration of conversion shares on Form S-1 or S-3.
CERO Therapeutics Holdings, Inc. registered 729,596,950 shares of Common Stock via a Prospectus Supplement. The supplement attaches a Form 8-K that discloses the issuance of a convertible promissory note with a purchase price of $750,000 (principal face value $937,500) and an available facility up to $1,000,000.
The Note bears interest at 10% per annum, matures on August 6, 2027, and is convertible at the lesser of $0.05 or 80% of the average of the five lowest intraday trading prices during the 20 trading days before a conversion request, subject to a 4.99% beneficial ownership limit. The Prospectus Supplement states a registration statement will cover resale of shares issuable upon conversion.
CERO Therapeutics is supplementing its Form S-1 to register 729,596,950 shares of Common Stock via Prospectus Supplement No. 5.
The supplement attaches a Form 8-K disclosing a $750,000 convertible note (principal face value $937,500) that permits up to $1,000,000 of borrowings, bears 10% interest, matures on July 9, 2027, and is convertible into common stock at the lesser of $0.05 or 80% of the average of the five lowest intraday trading prices during the preceding 20 days, subject to a 4.99% beneficial ownership limit. The Note requires the company to file a registration statement covering resale of conversion shares.
The Form 8-K also reports dismissal of auditor Wolf & Company, P.C. and appointment of Salberg & Company, P.A. effective February 13, 2026, with Wolf’s prior audit reports including an explanatory paragraph about substantial doubt as to going concern. The Board increased from six to seven members and appointed Eric Francois as a director, effective February 13, 2026.
Cero Therapeutics Holdings, Inc. has registered 729,596,950 shares of common stock under a Form S-1, and this Prospectus Supplement No. 4 updates that registration by incorporating information from a newly filed Current Report on Form 8-K.
The 8-K adds a poster presentation that the company prepared for the Transplantation and Cellular Therapy Meetings beginning on February 4, 2026, filed as Exhibit 99.1. Cero’s common stock trades on OTCQB under “CERO” and its public warrants trade on OTCID under “CEROW.” On February 3, 2026, the last quoted bid prices were $0.05 per share of common stock and $0.0068 per warrant.
The company is classified as an emerging growth company and highlights that investing in its securities involves a high degree of risk, directing readers to the Risk Factors section of the base prospectus. The poster is described as summary information and is intended to be read together with the company’s other SEC filings and public announcements.
CERO Therapeutics Holdings, Inc. has filed a prospectus supplement tied to its Form S-1 registration statement covering 729,596,950 shares of common stock, updating the related prospectus with information from a new Form 8-K.
The Form 8-K notes that the company has released an investor presentation for use in meetings and issued a press release titled “CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion-Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML.” The common stock trades on OTCQB under “CERO” and the public warrants trade on OTCID under “CEROW.”
CERO Therapeutics Holdings, Inc. supplements its prospectus covering 729,596,950 shares of common stock by attaching a new current report. The update centers on stockholder approvals from a recent special meeting.
At that meeting, stockholders approved an amendment to the 2024 Equity Incentive Plan to increase the shares of common stock available for issuance, and eligible for incentive stock options, by 32,000,000 shares. As of the November 14, 2025 record date, there were 20,802,671 shares of common stock issued and outstanding and entitled to vote, and 52.82% of those shares were present, satisfying quorum requirements.
The company’s common stock trades on the OTCQB under the symbol “CERO”, and its public warrants trade on OTCID under “CEROW”. On December 19, 2025, the last quoted bid prices were $0.0965 per share of common stock and $0.0005 per warrant.
CERO Therapeutics Holdings, Inc. has an effective registration statement that covers 2,100,000 shares of common stock, and this prospectus supplement simply updates that registration by attaching the company’s latest Quarterly Report on Form 10-Q. The 10-Q shows that CERO, an early-stage immunotherapy developer, is advancing its lead T cell therapy CER-1236 in a Phase 1/1b trial for acute myelogenous leukemia and has a second IND cleared for NSCLC and ovarian cancer.
For the nine months ended September 30, 2025, CERO reported a net loss of $15.4 million, bringing its accumulated deficit to about $86.3 million. Cash, restricted cash and cash equivalents were $2.0 million as of September 30, 2025, while total current liabilities were significantly higher, and the company states there is substantial doubt about its ability to continue as a going concern without additional capital. CERO’s common stock was delisted from Nasdaq after an October 29, 2025 determination and now trades on the OTC Pink Sheets under the symbol CERO; there were 21,102,671 shares outstanding as of November 19, 2025.
CERO Therapeutics Holdings, Inc. is registering 12,500,000 shares of common stock under a supplemented Form S-1, with this prospectus supplement incorporating its latest Quarterly Report on Form 10-Q. The company’s stock now trades on the OTC Pink Sheets under “CERO,” recently quoted at $0.06 per share, with public warrants at $0.009.
The attached 10-Q for the quarter ended September 30, 2025 shows an early-stage immunotherapy business focused on engineered T cell therapies for cancer, including a Phase 1/1b AML trial of lead asset CER-1236, where three patients have been dosed, and a second IND accepted for NSCLC and ovarian cancer. CERO reported a net loss of $15.4 million for the nine months ended September 30, 2025 and an accumulated deficit of $86.3 million, with cash and cash equivalents of about $2.0 million and substantial doubt raised about its ability to continue as a going concern. As of November 19, 2025, 21,102,671 shares of common stock were outstanding.
Cero Therapeutics Holdings, Inc. filed a Prospectus Supplement updating its S-1 covering 12,500,000 shares of common stock, incorporating a Current Report on Form 8-K.
The update discloses that a Nasdaq Hearings Panel denied continued listing of the common stock, with trading on Nasdaq to be suspended at the open on October 31, 2025. The company has requested review by the Nasdaq Listing and Hearing Review Council and has begun the process to trade on the OTC Markets, noting that OTC venues are typically less liquid and may adversely affect trading price and volume. Cero is also considering other exchange listings.
The company states it intends to continue its clinical trials, including ongoing dosing. Early observations for CER-1236 in three AML patients at an initial low dose included rapid cell expansion and no observed toxicity, and one patient continues on trial; the company plans to advance to a higher dose and is evaluating financing alternatives to fund operations.
Cero Therapeutics Holdings, Inc. filed Prospectus Supplement No. 11 to its S‑1, covering 2,100,000 shares of common stock and updating its prospectus with an attached Form 8‑K. The supplement incorporates the company’s latest disclosure into the existing offering materials.
The company reports that a Nasdaq Hearings Panel denied continued listing; CERO common stock will be suspended from trading at the open on October 31, 2025. Cero has requested review by the Nasdaq Listing and Hearing Review Council and has begun the process to trade on the OTC Markets, noting that OTC is a less liquid venue that may materially affect trading price and volume. The company is also considering other exchange listing alternatives.
Cero plans to continue its clinical trials of CER‑1236. Early observations in the first three AML patients at an initial low dose showed rapid CER‑1236 cell expansion with no toxicity; a second patient receiving three successive low doses remains on trial. The company is progressing to a planned higher dose and is reviewing cash resources and financing alternatives, with no assurance of obtaining financing.
CERo Therapeutics Holdings filed a prospectus supplement updating its S-1 that registers 2,100,000 shares of common stock. The supplement attaches recent current reports on Form 8-K.
Nasdaq prices on October 22, 2025 were $2.01 for CERO and $0.019 for CEROW. The attached 8-Ks detail a private placement: a Securities Purchase Agreement for up to $7 million of Series E convertible preferred stock (stated value $1,000 per share). An SPA amendment increased the initial closing to approximately $2.25 million, with 3,816 Series E shares issued, and leaves $4.75 million available for additional closings. The fixed conversion price is $4.1625 per share, with stockholder approval mechanics and potential price adjustments for future issuances. Holders of existing Series C and D preferred consented to pari passu ranking and their conversion prices were set at $1.76. The company agreed to file a registration statement to register for resale the common stock issuable upon conversion of the Series E preferred.
CERO Therapeutics Holdings filed Prospectus Supplement No. 4 to its Form S-1, covering 12,500,000 shares of common stock. The supplement incorporates recent Form 8-Ks from September 22, October 14, and October 16, 2025.
The October 14 and 16 updates detail a private placement of up to $7 million of Series E convertible preferred stock, including an initial closing of approximately $2.25 million for 3,816 Series E shares. The Series E has a stated value of $1,000 per share, a fixed conversion price of $4.1625 (subject to adjustments and alternate conversion pricing), and no voting rights. The company plans to seek stockholder approval to permit below-price conversions, targeting a preliminary proxy by October 31, a definitive proxy by November 30, and a meeting by December 31, 2025. The filing also notes the Series C and D preferred shares’ conversion price was reduced to $1.76.
On Nasdaq, as of October 22, 2025, CERO closed at $2.01 and CEROW at $0.019 per warrant.